EN | UA
EN | UA

Help Support

Back

Safety and efficacy of crisaborole for treatment of atopic dermatitis

Safety and efficacy of crisaborole for treatment of atopic dermatitis Safety and efficacy of crisaborole for treatment of atopic dermatitis
Safety and efficacy of crisaborole for treatment of atopic dermatitis Safety and efficacy of crisaborole for treatment of atopic dermatitis

This study aimed to explore safety and effectiveness of two crisaborole (a non-steroidal anti-inflammatory phosphodiesterase 4 inhibitor) therapeutic regimens for managing pediatric and adult patients with atopic dermatitis.

See All

Key take away

In patients aged ≥2 years with mild-to-moderate atopic dermatitis, both once daily and twice daily crisaborole regimens (particularly crisaborole twice daily) displayed efficacy and good tolerability.

Background

This study aimed to explore safety and effectiveness of two crisaborole (a non-steroidal anti-inflammatory phosphodiesterase 4 inhibitor) therapeutic regimens for managing pediatric and adult patients with atopic dermatitis.

Method

In this randomized, phase 2b, double-blind study, each participant was allocated to one of the two age cohorts (≥12 years or 2-11 years) and randomized to 2% crisaborole ointment once daily or twice daily.  Overall, there were 81 participants (Cohort 1: 41 participants; Cohort 2: 40 participants). All the participants had two target lesions that were each randomized to either vehicle or crisaborole at the baseline and managed for two weeks.

Occurrence of treatment-emergent noxious events and an alteration from the baseline in Investigator's Static Global Assessment (ISGA) and pruritic evaluations (Cohort 2: Caregiver-Reported Itch Severity numeric rating scale [NRS] and Itch Severity Scale Self-Report; Cohort 1: Peak Pruritus NRS) were the secondary outcomes ascertained. An alteration from the baseline in total sign score (TSS) in the vehicle or crisaborole-treated target lesions on the 15th day was the major outcome ascertained. 

Result

Compared to vehicle-treated lesions, crisaborole-treated lesions demonstrated a substantial decline in TSS at day 15. In both cohorts 1 and 2, a numerically greater decline in TSS was witnessed with crisaborole twice daily when compared to crisaborole once daily, as shown in Figures 1a and b.

Regardless of the regimen or cohort, crisaborole-treated lesions illustrated more reductions in the secondary endpoints (ISGA, pruritic assessments) when compared to the vehicle-treated lesions. Mild treatment-emergent adverse events were noted with application site irritation being the most frequently reported adverse event.


Conclusion

A 2% crisaborole appears to be a viable management option for pediatric and adult patients suffering from atopic dermatitis.

Source:

The Journal of Dermatology

Article:

A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis

Authors:

Kayo Fujita et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: